From discovery to delivery: making therapies reach patients faster
Pharmaceutical Technology
JUNE 22, 2025
David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for purpose.
Sun.Jun 22, 2025
130 
STAT+: Novo Nordisk’s amylin obesity drug keeps performing like Zepbound
STAT News
JUNE 22, 2025
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not be the standout treatment that investors had hoped for. Novo previously reported that patients on CagriSema lost 20% of their weight in a 68-week Phase 3 trial when looking at all participants, a similar level of weight loss seen in Zepbound studies.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
We’re at the Crossroads: Affordable Healthcare or Continued Suffering?
World of DTC Marketing
JUNE 22, 2025
The American healthcare system stands at a pivotal intersection. On one path lies a vision of accessible, affordable care that prioritizes patients over profits. On the other hand, we persist in a status quo marked by soaring medical costs, heartbreaking choices between medication and necessities, and millions of people suffering because healthcare remains unaffordable.
Early Lipids Boost Cerebellar Metabolism in Preemies
Scienmag
JUNE 22, 2025
In a groundbreaking study set to redefine neonatal nutritional strategies, researchers have shed new light on the crucial role of early parenteral lipid administration in supporting cerebellar neurometabolism among preterm infants at term-equivalent age. Published in the Journal of Perinatology in 2025, this pivotal research meticulously explores how tailored lipid intake can significantly influence the delicate neurodevelopmental processes during a critical window of brain growth.
How to Turn “Check-the-Box” Compliance Trainings Into Real Learning
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
Roche’s NXT007 Shows Early Promise for Normalising Clotting in Haemophilia A
The Pharma Data
JUNE 22, 2025
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its early-stage clinical development program evaluating NXT007, a next-generation investigational bispecific antibody designed for people living with hemophilia A.
“‘Closed Loop’ Learning Barriers Limit Doctors’ Use of Life-Saving Bedside Ultrasound”
Scienmag
JUNE 22, 2025
A groundbreaking study has revealed why a cutting-edge medical imaging technique known as Point-of-Care Ultrasound (POCUS) often fails to become a staple in many doctors’ daily practice despite its promise for saving lives. POCUS, which involves bedside ultrasound scanning using portable devices, offers clinicians rapid diagnostic insights into critical conditions such as heart failure, pulmonary edema, or internal bleeding—ailments that frequently demand immediate intervention.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Multiple Deprivations Undermine Child Vaccination in Latin America
Scienmag
JUNE 22, 2025
In a groundbreaking new study published in the International Journal for Equity in Health , researchers have shed light on a critical and complex public health issue affecting Latin America and the Caribbean: the underperformance of basic child vaccination programs. Drawing from an extensive cross-sectional analysis encompassing 18,136 children across 211 distinct regions in 15 countries, this study unpacks how a constellation of overlapping social, economic, and infrastructural deprivations act
Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes
JAMA Internal Medicine
JUNE 22, 2025
This systematic review and meta-analysis examines the association of an early invasive strategy vs a conservative strategy with clinical outcomes for patients 70 years or older who present with acute coronary syndrome.
Impact of Maternal Age on Infant Development: New Scientific Insights
Scienmag
JUNE 22, 2025
The phenomenon of women giving birth after the age of 40 has become increasingly prevalent in many parts of the world, reflecting broader social changes such as later family planning and advances in reproductive health technologies. However, this demographic shift brings with it a complex set of challenges and risks, particularly concerning neonatal outcomes.
Exelixis: Zanzalintinib Combo Boosts Survival in Phase 3 Colorectal Cancer Trial
The Pharma Data
JUNE 22, 2025
Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis , has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a major milestone in the development of its investigational therapy zanzalintinib. The trial assessed the combination of zanzalintinib, a next-generation tyrosine kinase inhibitor (TKI), with the immune checkpoint inhibitor atezolizumab (marketed as Tecentriq® by Genentech/Roche),
Clinical Research White Paper – Enhancing Transparency & Efficiency Throughout the Trial Lifecycle
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Diabetes Deprescribing in Older Adults
JAMA Internal Medicine
JUNE 22, 2025
This randomized clinical trial compares physician academic detailing with or without patient previsit activation for insulin and/or sulfonylurea deprescribing in older patients with diabetes.
CHMP Recommends EU Approval of Sarclisa for Newly Diagnosed Multiple Myeloma
The Pharma Data
JUNE 22, 2025
Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy for adult patients newly diagnosed with multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT).
This abortion method doesn't involve doctors — and many of them consider it safe
NPR Health - Shots
JUNE 22, 2025
Roe v. Wade was overturned in 2022, she found another way to support patients with limited access to abortions.'/> A growing body of research demonstrating the safety and effectiveness of self-managed abortion with pills, coupled with the global pandemic in 2020 and the fall of Roe in 2022, has many U.S. doctors changing their views.
Novo Nordisk’s CagriSema Shows 22.7% Weight Loss in REDEFINE 1 Study Published in NEJM
The Pharma Data
JUNE 22, 2025
Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity and overweight, Novo Nordisk today announced the publication of pivotal Phase 3 REDEFINE 1 trial results in the New England Journal of Medicine (NEJM). The investigational dual hormone therapy CagriSema , a combination of semaglutide (GLP-1 receptor agonist) and cagrilintide (amylin analogue) , demonstrated c
Can Your Organization Spot a Conflict Before It’s a Crisis?
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
BioTech 365
JUNE 22, 2025
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 … Continue reading →
Femtosecond Polygonal Optical Vortices from Quasi-Degenerate Laser
Scienmag
JUNE 22, 2025
In a groundbreaking advancement poised to redefine the frontiers of ultrafast photonics, researchers led by Liu, Yan, and Wang have pioneered the generation of femtosecond polygonal optical vortices utilizing a mode-locked quasi-frequency-degenerate laser. Published in the prestigious journal Light: Science & Applications in 2025, this novel methodology not only pushes the envelope of laser beam manipulation but also unveils new possibilities across multiple domains from high-resolution imag
New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
BioTech 365
JUNE 22, 2025
New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing Data Presented at the 2025 American Society for … Continue reading →
Impact of Recycled Plastics on Hormonal Balance and Metabolic Processes
Scienmag
JUNE 22, 2025
In a significant revelation regarding the complexities of plastic recycling, a groundbreaking study has emerged, led by researchers from the University of Gothenburg and Leipzig. This research sharply underlines the unanticipated dangers associated with recycled polyethylene plastic, specifically how it can leach hazardous chemicals into water. A striking finding from this study is that a single pellet of recycled plastic can harbor over 80 different chemicals, illustrating the substantial risks
White Paper - A Roadmap to AI Data Readiness in R&D Labs
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
BioTech 365
JUNE 22, 2025
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A Positive phase I/II data … Continue reading →
Last Friday was a Good Day for Those Who Want to Litigate Against the Federal Government.
FDA Law
JUNE 22, 2025
By JP Ellison — Last Friday, the Supreme Court delivered a trio of decisions making it easier to litigate against the federal government. The facts and law in each case matter, and as is often the case when the Supreme Court “decides” an issue, much remains to be seen. That said, it’s hard to see how the score on Friday wasn’t 3 for regulated industry and 0 for the federal government.
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
BioTech 365
JUNE 22, 2025
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by … Continue reading →
Electric Vehicle Industry: Global Evolutionary Game Analysis
Scienmag
JUNE 22, 2025
The electric vehicle (EV) industry stands at the forefront of a global transformation, intricately shaped by a dynamic interplay of technology, policy, market demand, and infrastructure. As nations chart their course toward sustainable transportation, the comparative development of this sector across the United States, the European Union, China, and Japan reveals a complex mosaic of strategic alignments and divergences.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
NEL Animal Cardiovascular Center Achieves World’s First Surgical Correction of Complex VSD in Canine Patient
BioTech 365
JUNE 22, 2025
NEL Animal Cardiovascular Center Achieves World’s First Surgical Correction of Complex VSD in Canine Patient NEL Animal Cardiovascular Center Achieves World’s First Surgical Correction of Complex VSD in Canine Patient ANYANG, South Korea–(BUSINESS WIRE)–#Canine—NEL Animal Cardiovascular Center, a private 24-hour … Continue reading →
In this rural Colorado valley, cuts to Medicaid would have vast ripple effects
NPR Health - Shots
JUNE 22, 2025
Cuts to Medicaid moving through Congress would shake up health care in the scenic San Luis Valley — with negative downstream effects on local jobs, businesses and education.
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
BioTech 365
JUNE 22, 2025
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated … Continue reading →
Your Brain Has a Hidden Rhythm, And It May Reveal How Smart You Are
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 22, 2025
The smarter you are, the more your brain is in sync with its own secret rhythm, a new study has found. When your brain works particularly hard, different regions of the brain sync up as they work together to perform tasks that require a higher cognitive load.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
BioTech 365
JUNE 22, 2025
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine Novo Nordisk A/S: CagriSema 2.4 mg / 2.
IISc develops artificial metal-based novel nanozyme to prevent abnormal blood clotting
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 22, 2025
Researchers at the Indian Institute of Science (IISc) have developed an artificial metal-based nanozyme that can possibly be used to clamp down on abnormal blood clotting caused by conditions like pulmonary thromboembolism.
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
BioTech 365
JUNE 22, 2025
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement Ad hoc announcement pursuant … Continue reading →
Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift
BioTech 365
JUNE 22, 2025
Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift Dr.
Let's personalize your content